drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, gene-modified anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy given as a single infusion; engineered patient T cells target CD19 to deplete B cells/plasmablasts and reduce autoantibody-mediated pathology in idiopathic inflammatory myopathies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express an anti-CD19 chimeric antigen receptor; after infusion, these CAR T cells recognize and kill CD19-positive B cells and plasmablasts, depleting autoreactive B-cell populations, lowering autoantibody production, and attenuating B cell–driven inflammation.
drug_name
Rapcabtagene autoleucel (YTB323)
nct_id_drug_ref
NCT06665256